← Patent-cliff monitor small molecule DOPTELET SPRINKLE AVATROMBOPAG MALEATE
Loss of exclusivity July 2032 FDA regulatory exclusivity expiry
Company AkaRx → See this company's full patent-cliff portfolio Drug detail Brand name DOPTELET SPRINKLE Active ingredient AVATROMBOPAG MALEATE Strength EQ 10MG BASE Dosage form GRANULE Route ORAL Modality Small molecule FDA approval July 2025 Marketing status RX
Listed patents Patent Expires Type 7638536 July 2027 substance, product
Regulatory exclusivity Code Expires ODE-548 July 2032 NP July 2028
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the FDA regulatory exclusivity expiry; estimates are projections, not legal advice.